← All trials
NCT05173987
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 3, 2022
- Primary completion
- Jul 17, 2026
- Completion date
- Jul 17, 2026
- First posted
- Dec 30, 2021
- Last posted
- Dec 22, 2022
- Enrollment
- 350
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MerckLead sponsor
- MerckStudy director
- Gynecologic Oncology GroupCollaborator
- European Network for Gynaecological Oncological TrialCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.